Advertisement

Topics

Ablynx nv Company Profile

00:35 EDT 25th September 2017 | BioPortfolio

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Location

Technologiepark 4
Ghent
Zwijnaarde
9052
Belgium

Contact

Phone: 32 9 261.06.32
Fax: 32 9 261.06.28
Email: info@ablynx.com


News Articles [60 Associated News Articles listed on BioPortfolio]

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the...

Ablynx enters $2.8bn Nanobody deal with Sanofi

Sanofi is Ablynx NV’s latest Big Pharma partner through a new deal involving Ablynx’s Nanobodies that could be worth up to $2.8bn to the biotech.

Ablynx: ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES

REGULATED INFORMATION GHENT, Belgium, 20 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a research collaboration and global exclusive licensing a...

Ablynx: ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

GHENT, Belgium, 26 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for caplacizumab, th...

Ablynx Wins €15M from Merck KGaA as Arthritis Candidate Nears Clinic

Ablynx said today it will receive a €15 million ($16.9 million) milestone payment from Merck KGaA after the pharma giant approved its preclinical package for ALX-1141, setting the stage for advancin...

Ablynx: ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER

GHENT, Belgium, 13 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June ...

Nanobody handover nets Ablynx milestone payment

Belgian biotech Ablynx has completed the preparation of a pre-clinical package for the novel Nanobody,…

Sanofi signs deal with Ablynx for inflammatory disease study

Ablynx will give Sanofi access to its platform for the development of nanobody-based drugs to treat various immune-mediated i -More- 

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therap...

More Information about "Ablynx nv" on BioPortfolio

We have published hundreds of Ablynx nv news stories on BioPortfolio along with dozens of Ablynx nv Clinical Trials and PubMed Articles about Ablynx nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ablynx nv Companies in our database. You can also find out about relevant Ablynx nv Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record